FRANKFURT (Reuters) - Drugmaker Bayer AG said on Tuesday it will this month file for approval of its experimental haemophilia drug Bay 81-8973, based on its established Kogenate brand, as it seeks to build a range of treatments against the hereditary bleeding disorder.
The German company in March unveiled plans to spend more than 500 million euros ($622 million) to set up haemophilia drug production sites in Germany, in a sign of confidence in its development pipeline.
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal16
23:37 Here’s Why Netflix’s Share Price Just Hit a New All-Time High3
21:52 Netflix nears 94 million subscribers 10 years after streaming launch16
22:33 Allergan to pay $15 million over failing to disclose merger talks18